GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Price-to-Tangible-Book

Veru (VERU) Price-to-Tangible-Book

: 4.61 (As of Today)
View and export this data going back to 1990. Start your Free Trial

As of today (2024-04-19), Veru's share price is $1.4101. Veru's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.31. Hence, Veru's Price to Tangible Book Ratio of today is 4.61.

The historical rank and industry rank for Veru's Price-to-Tangible-Book or its related term are showing as below:

VERU' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.03   Med: 5.72   Max: 81.71
Current: 4.55

During the past 13 years, Veru's highest Price to Tangible Book Ratio was 81.71. The lowest was 1.03. And the median was 5.72.

VERU's Price-to-Tangible-Book is ranked worse than
63.61% of 1223 companies
in the Biotechnology industry
Industry Median: 2.7 vs VERU: 4.55

A closely related ratio is called PB Ratio. As of today, Veru's share price is $1.4101. Veru's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.35. Hence, Veru's P/B Ratio of today is 3.99.


Veru Price-to-Tangible-Book Historical Data

The historical data trend for Veru's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.67 10.48 4.82 12.89 5.17

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.12 9.75 3.86 5.17 2.35

Competitive Comparison

For the Biotechnology subindustry, Veru's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Veru's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Veru's Price-to-Tangible-Book falls into.



Veru Price-to-Tangible-Book Calculation

Veru's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.4101/0.306
=4.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Veru Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Veru's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus